Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency ratio (binding) | = 1.4 | Inhibition of V-ATPase-driven proton transport in membrane vesicles derived from bovine chromaffin granules (bCG); Potency ratio expressed as IC50 of compound/IC50 of baf A1 | ChEMBL. | 9599238 |
Potency ratio (binding) | = 1.4 | Inhibition of V-ATPase-driven proton transport in membrane vesicles derived from chicken osteoclasts (cOc); Potency ratio expressed as IC50 of compound/IC50 of baf A1 | ChEMBL. | 9599238 |
Potency ratio (binding) | = 1.4 | Inhibition of V-ATPase-driven proton transport in membrane vesicles derived from chicken osteoclasts (cOc); Potency ratio expressed as IC50 of compound/IC50 of baf A1 | ChEMBL. | 9599238 |
Potency ratio (binding) | = 1.4 | Inhibition of V-ATPase-driven proton transport in membrane vesicles derived from bovine chromaffin granules (bCG); Potency ratio expressed as IC50 of compound/IC50 of baf A1 | ChEMBL. | 9599238 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.